0 27

Cited 0 times in

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Authors
 Hyun Cheol Chung  ;  Sarina A Piha-Paul  ;  Jose Lopez-Martin  ;  Jan H M Schellens  ;  Steven Kao  ;  Wilson H Miller Jr  ;  Jean-Pierre Delord  ;  Bo Gao  ;  David Planchard  ;  Maya Gottfried  ;  Alona Zer  ;  Shadia I Jalal  ;  Nicolas Penel  ;  Janice M Mehnert  ;  Ignacio Matos  ;  Jaafar Bennouna  ;  Dong-Wan Kim  ;  Lei Xu  ;  Suba Krishnan  ;  Kevin Norwood  ;  Patrick A Ott 
Citation
 JOURNAL OF THORACIC ONCOLOGY, Vol.15(4) : 618-627, 2020-04 
Journal Title
 JOURNAL OF THORACIC ONCOLOGY 
ISSN
 1556-0864 
Issue Date
2020-04
Keywords
Immunotherapy ; Pembrolizumab ; SCLC ; Third-line therapy
Abstract
Introduction: Pembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC. Methods: Eligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)-positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review. Results: Eighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5-48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4-29.4); two patients had complete response (one with a PD-L1-positive tumor), and 14 patients had partial response (13 with PD-L1-positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events. Conclusions: Pembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated.
Full Text
https://www.sciencedirect.com/science/article/pii/S155608641933850X
DOI
10.1016/j.jtho.2019.12.109
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/176014
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links